Nabi, Sanofi Pasteur sign supply, manufacturing agreement for rabies product

By Elaine Rigoli

Tampa, Fla., April 26 - Nabi Biopharmaceuticals has signed an agreement with Sanofi Pasteur for the production of Imogam Rabies-HT, which provides passive protection when given immediately to individuals exposed to the rabies virus.

Under the agreement, Nabi will fractionate human plasma containing antibodies to the rabies virus and ship the partially manufactured product to Sanofi Pasteur for completion of production at its manufacturing facility.

Imogam Rabies-HT is used in combination with a rabies vaccine to prevent infection caused by exposure to the rabies virus in people who have never been vaccinated against rabies.

Although rabies among humans is rare in the United States, an estimated 40,000 individuals receive a post-exposure prevention treatment each year, the company said.

Sanofi Pasteur, based in Lyon, France, is part of the Sanofi-Aventis Group.

Based in Boca Raton, Fla., Nabi develops products that fight serious medical conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.